Age-related macular degeneration (AMD) remains the leading cause of visual loss in adults older than 65 years. Retinal angiomatous proliferation (RAP) is a newly recognized manifestation of exudative AMD that has a poor natural history and demonstrated resistance to treatment with conventional laser photocoagulation. A novel surgical technique has been developed in this pilot series that shows promise in the treatment of this subtype of neovascular lesions. Through specific surgical lysis of the feeding arteriole and draining venule of an RAP lesion, improvement in visual acuity has been noted. This has been correlated with resolution of intraretinal edema and flattening of associated pigment epithelial detachment, which was confirmed by fluorescein angiography, optical coherence tomography, and high-speed indocyanine green angiography.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archopht.121.4.558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction of fellow eye neovascularization in type 3 macular neovascularization (Retinal angiomatous proliferation) using deep learning.
PLoS One
October 2024
Department of Ophthalmology, Kim's Eye Hospital, Seoul, South Korea.
Purpose: To establish a deep learning artificial intelligence model to predict the risk of long-term fellow eye neovascularization in unilateral type 3 macular neovascularization (MNV).
Methods: This retrospective study included 217 patients (199 in the training/validation of the AI model and 18 in the testing set) with a diagnosis of unilateral type 3 MNV. The purpose of the AI model was to predict fellow eye neovascularization within 24 months after the initial diagnosis.
Factors Affecting Visual Acuity After Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration: A Multicenter Study in Japan.
J Clin Med
October 2024
Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Article Synopsis
- Anti-VEGF therapy is the main treatment for neovascular age-related macular degeneration (nvAMD), and this study investigates factors influencing visual outcomes for treated patients.
- Conducted in Japan with 182 elderly patients, the study examines how age, baseline vision, and eye conditions affect visual acuity after one year of treatment with ranibizumab or aflibercept.
- Key findings reveal that younger age, absence of intraretinal fluid and pigment epithelial detachment, and lack of smoking or diabetes history can lead to better visual prognosis in nvAMD patients.
Diabetic uveopathy.
Surv Ophthalmol
November 2024
Eye Institute, Affiliated Hospital of Nantong University, China. Electronic address:
Diabetes can involve several ocular structures -- including the cornea, lens, and retina -- and cause vascular and neural changes in these tissues. Although retinopathy is the most common ocular complication of diabetes, uveopathy can also be observed. This includes vascular, neural, muscular, and basement membrane changes.
View Article and Find Full Text PDFImportance of optical coherence tomography raster scans in early detection of active fellow-eye neovascularization in unilateral neovascular age-related macular degeneration.
BMC Ophthalmol
August 2024
Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea.
Purpose: To investigate the incidence of and risk factors for failure of detection of active fellow-eye neovascularization on optical coherence tomography(OCT) crosshair scans in patients with unilateral neovascular age-related macular degeneration(AMD).
Methods: In this retrospective study, patients who experienced the development of active neovascularization in the fellow eye during the follow-up period were included(n = 75). Cases in which the neovascularization in the fellow eye could be identified solely through crosshair scans were defined as the crosshair scan detection group(n = 63).
Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan.
Ophthalmol Ther
October 2024
Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Article Synopsis
- The study assessed the cost-effectiveness of anti-VEGF therapies for neovascular age-related macular degeneration (nAMD), focusing on societal and patient perspectives in Japan.
- A Markov model simulated treatment outcomes for various subtypes of nAMD, comparing ranibizumab biosimilar to aflibercept and other treatment regimens in terms of quality-adjusted life years (QALYs) and costs.
- Results showed that ranibizumab biosimilar had varying incremental QALYs and costs depending on the nAMD subtype and perspective, indicating a complex evaluation of its economic value relative to other treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!